HHS expands U.S.-based pharmaceutical manufacturing to get drugs to hospitals faster
May 21, 2020 / Susan Morse, Managing Editor
The Department of Health and Human Services will work with a team of private industry partners led by Phlow Corporation of Richmond, Virginia, to expand pharmaceutical manufacturing in the United States to provide medicines needed during COVID-19 and future public health emergencies.
The U.S. government and Phlow are developing a prioritized list of active pharmaceutical ingredients and finished medicines critically needed by healthcare systems.
The Phlow-led team will provide immediate, U.S.-based capacity to produce the active pharmaceutical ingredients and the chemical compounds for ingredients needed to help alleviate or prevent drug shortages.
The drug ingredients will be manufactured at facilities in the United States, including a new facility to be built in Virginia.
